From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
No displayed matched alternative is a general benefit.
GUSELKUMAB · Limited Use, codes 658
(guselkumab injection/guselkumab for injection) is indicated for:
• the treatment of adult patients with moderately to severely active ulcerative colitis.
1.1 Pediatrics
Plaque Psoriasis
• (6 years to 17 years): TREMFYA (guselkumab injection) is indicated for the treatment of
pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who
are candidates for systemic therapy or phototherapy (see 4.1 Dosing Considerations).
PM: https://pdf.hres.ca/dpd_pm/00085777.PDF; date 2026-08-14; DIN 02469758; fetched 2026-09-10
Product monograph
IXEKIZUMAB · Limited Use, codes 526
Ankylosing Spondylitis
TALTZ is indicated for the treatment of adult patients with active ankylosing spondylitis who
have responded inadequately to, or are intolerant to conventional therapy.
PM: https://pdf.hres.ca/dpd_pm/00080067.PDF; date not captured; DIN 02455102; fetched 2026-09-10
Product monograph
RISANKIZUMAB · Limited Use, codes 574
• the treatment of adult patients with moderately to severely active ulcerative colitis who have had
an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic
treatment, or a Janus kinase (JAK) inhibitor.
PM: https://pdf.hres.ca/dpd_pm/00085642.PDF; date 2026-07-08; DIN 02519283; fetched 2026-09-10
Product monograph
SECUKINUMAB · Limited Use, codes 476
Axial spondyloarthritis (axSpA)
Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)
COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis who have
responded inadequately to conventional therapy (see 14.1.3 Axial spondyloarthritis (axSpA),
Ankylosing spondylitis).
PM: https://pdf.hres.ca/dpd_pm/00080972.PDF; date not captured; DIN 02529653; fetched 2026-09-10
Product monograph
UPADACITINIB · Limited Use, codes 637, 684 (1), Limited Use, codes 684 (2)
RINVOQ (upadacitinib) Page 5 of 108
Unclassified / Non classifié
Ulcerative Colitis
RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative
colitis (UC) who have demonstrated prior treatment failure, i.e., an inadequate response to, loss of
response to, or intolerance to at least one of conventional, and/or biologic therapy.
PM: https://pdf.hres.ca/dpd_pm/00085368.PDF; date 2026-07-14; DIN 02495155; fetched 2026-09-10
Product monograph
USTEKINUMAB · Limited Use, codes 669, 670, 671, 672 (5), Limited Use, codes 669, 671, 672, 742 (4), Limited Use, codes 668, 669, 671, 672 (6), Limited Use, codes 669, 671, 672, 733 (3), Limited Use, codes 671, 672 (5)
(ustekinumab) is indicated for the treatment of adult patients with moderately to
severely active ulcerative colitis who have had an inadequate response with, lost response to, or were
intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
1.1 Pediatrics
Pediatrics (6-17 years of age): Jamteki (ustekinumab) is indicated for the treatment of chronic moderate to
severe plaque psoriasis in pediatric patients (children and adolescents) from 6 to 17 years of age, who are
inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.
PM: https://pdf.hres.ca/dpd_pm/00077781.PDF; date November 9, 2023; DIN 02543036; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-09-22